The clinical trial landscape is increasingly shaped by complexity, particularly in oncology. Precision medicine protocols, narrow eligibility criteria, and evolving therapeutic approaches make strong site partnerships essential. For TD2, a specialty contract research organization (CRO) focused on oncology, that challenge is met not through scale, but through agility, intentional listening, and strategic collaboration.
In this Collaborate Forward spotlight, we met with April Coburn, Director of Site Services at TD2 to explore how TD2 is working closely with investigative sites to clarify expectations, communicate around capability, and establish shared key performance indicators (KPIs) that benefit all stakeholders…
